Belgium· BE-AMP-SAM666048-00
Ojemda 25 mg/ml
A tovorafenib product containing tovorafenib, registered in Belgium by Ipsen Pharma. The same ATC class is registered in 9 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Tovorafenib is registered in 9 of 19 countries.
Countries holding a registration under ATC L01EC04 (tovorafenib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Tovorafenib · ATC L01EC04
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Tovorafenib
- Manufacturer
- Ipsen Pharma
- Country
- Belgium (BE)
- ATC code
- L01EC04
- ATC class
- Tovorafenib
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tovorafenib in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandOjemda 25 mg/ml, Pulver zur Herstellung einer Suspension zum EinnehmenIPSEN Pharma Schweiz GmbH
- CzechiaOJEMDAIPSEN PHARMA S.A.S., Paříž
- FinlandOjemdaIpsen Pharma
- IcelandOjemdaIpsen Pharma
- NetherlandsOjemda 25 mg/ml poeder voor suspensie voor oraal gebruikIpsen Pharma
- PolandOjemdaIpsen Pharma
- SwedenOjemda 25 mg/ml Pulver till oral suspensionIpsen Pharma
- United StatesOJEMDADay One Biopharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ojemda
- Liechtenstein · Ojemda
- Norway · Ojemda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ac082acf-57aa-47e6-9d74-8452e039531e GET /v1/drugs/ac082acf-57aa-47e6-9d74-8452e039531e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for oral suspension",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ojemda 25 mg/ml",
"name_fr": "Ojemda 25 mg/ml",
"name_nl": "Ojemda 25 mg/ml",
"amp_code": "SAM666048-00",
"strengths": [
"300.0000",
"300.0000"
],
"pack_count": 1,
"substances": [
"Tovorafenib",
"Mannitol",
"Sodium Laurilsulfate"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Tovorafenib",
"authorisation_numbers": [
"EU/1/26/2025/004"
]
}See everything about tovorafenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.